Team:EPF-Lausanne/Safety
From 2011.igem.org
Welcome
Safety
The 2011 EPFL iGEM team has taken two approaches to its engineering work on transcription factors: one is in vivo and the other is in vitro. Neither presents any form of unusual safety risk. Nevertheless, we should highlight a few aspects of the work that present some risk to the public and to the researcher.
§ The in vivo manipulation of E. coli using various antibiotics, like ampicillin and kanamycin, always presents a minimal amount of risk to those who would be exposed to a resistant strain.